The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Real-world outcomes of 2L carboplatin and pemetrexed in EGFRm NSCLC
Igor Gómez-Randulfe, MBBS, The Christie NHS Foundation Trust, Manchester, UK, discusses findings from a real-world multicentre analysis evaluating second-line carboplatin plus pemetrexed in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC) following first-line osimertinib. Outcomes included modest response rates, progression-free survival, and overall survival, with toxicity leading to dose reductions or discontinuation in some patients. These results reflect limited efficacy of chemotherapy in this setting and underscore the need for improved strategies beyond current treatment options. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know from the clinical trials that the second-line chemotherapy, carboplatin-based chemotherapy has a limited efficacy, but we don’t have a lot of data from the real world. So we have run a multicentric study showing that one-third of patients respond to carboplatin and pemetrexed after osimertinib, the PFS is consistent with the previously presented data in clinical trials, but the overall survival is shorter, about nine months, the median overall survival, which is not surprising considering that the characteristics of those patients are not the same as those recruited for clinical trials...
We know from the clinical trials that the second-line chemotherapy, carboplatin-based chemotherapy has a limited efficacy, but we don’t have a lot of data from the real world. So we have run a multicentric study showing that one-third of patients respond to carboplatin and pemetrexed after osimertinib, the PFS is consistent with the previously presented data in clinical trials, but the overall survival is shorter, about nine months, the median overall survival, which is not surprising considering that the characteristics of those patients are not the same as those recruited for clinical trials. They are less fit with a higher incidence of brain metastasis and therefore the survival is shorter.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
